Deciding priorities in Pharma by Koehler, Maria
It is commonly assumed that the primary objective of 
Pharma is to generate and maximize proﬁ   t to share-
holders rather than to serve humanity by the prevention 
and cure of disease and furthering science. Pharma is also 
felt to lack an incentive to fund and deliver personalized 
medicines, so it is up to the scientiﬁ  c community to do 
that (AT Fojo, Head of the Experimental Th  erapeutics 
Section, NCI at AACR 2010). Meanwhile, there are 
doubts within Pharma itself: ‘increasing regulatory 
requirements, related escalating costs of development, 
and well publicized product withdrawals are leading 
those in the industry and its investors to wonder where 
future value can be realized,’ (Ken Fyvie, expert in 
commercial strategy).
Despite this perceived pessimism, I assert to you today, 
that because of the rapid advances in genomics, imaging, 
and tumor cell biology, Pharma’s priorities are now more 
closely aligned with those of academia than ever before.
Nearly every eﬀ  ective targeted agent has a biomarker 
that can predict response. While somatic genetic altera-
tions in the tumor are the primary determinant of 
response to targeted therapy, multiple somatic genetic 
abnormalities are present in each tumor so both ﬁ  nding 
the critical mutations and proving that these were in fact 
driving tumorigenesis was and remains challenging. 
However, imatinib, trastuzumab, geﬁ  tinib/erlotinib, 
tamoxi  fen and many other therapeutics on the market 
prove that targeting speciﬁ  c biomarkers can be successful 
in both hematological and solid tumor malignancies. 
Targeting can bring signiﬁ  cant beneﬁ  t to patients and 
unexpectedly high proﬁ  ts to Pharma.
Pharma now understands the value of targeting speciﬁ  c 
genetic abnormalities even in small populations. Th  is 
‘low hanging fruit’ still requires better understanding on 
how best to demonstrate the treatment to be safe and 
eﬀ   ective in these niches. Conventional approaches to 
drug development need to be challenged. Th  e need to 
compare highly eﬀ  ective targeted agents to standard of 
care chemotherapy, the lack of biomarker testing in the 
community setting, tissue availability, and the ability to 
receive optimal pricing for higher responses in a smaller 
population are but a few of the challenges.
A perfect example of moving clearly in the direction 
science brings us is the Pﬁ   zer compound crizotinib 
(PF-02341066), which is a dual c-Met and ALK inhibitor 
that was initially developed with a c-Met focus [1]. 
c-MET is a frequently genetically altered receptor 
tyrosine kinase in human cancers (hereditary papillary 
renal cell carcinoma, 100%; sporadic papillary renal cell 
carcinoma, 13%; head and neck squamous cell carcinoma, 
10%; non-small cell lung cancer (NSCLC), 8%; and small 
cell lung cancer, 13%) or ampliﬁ  ed (gastric carcinoma, 5 
to 10%; colorectal carcinoma, 4% in primary tumors and 
20% in liver metastases; esophageal adenocarcinoma, 5 to 
10%). Th  e other kinase inhibited was an anaplastic 
lymphoma kinase (ALK), known to be present in a subset 
of chemo  sensitive anaplastic lymphomas, some 
neuroblastomas and in inﬂ  ammatory  myoﬁ  broblastic 
tumors, a very rare tumor. In 2007, Soda and colleagues 
published a Nature paper identifying ALK fusion genes 
[2]. Fortuitously, the phase I study was ongoing at that 
time with PF-02341066. Of the three objective 
responders in this phase I study, all had ALK 
translocations: one with inﬂ  ammatory  myo  ﬁ  bro  blastic 
sarcoma had a NPM-ALK translocation and two with 
NSCLC had a EML4-ALK translocation. Despite the 
extreme rarity of these abnormalities, Pﬁ  zer modiﬁ  ed the 
phase I protocol to recruit patients with NSCLC 
harboring ALK mutations and established a close 
collaboration with academia. Th  e collaborator adjusted 
the existing Abbott ﬂ  uorescent  in situ hybridi  zation 
(FISH) assay and served as the reference laboratory for 
detecting EML4-ALK translocations in tumor speci  mens 
for patients in the trial [3]. A formal collaboration with 
Abbott to develop a commercialized diagnostic followed.
In a single-agent study including 82 patients reported 
at the 2010 American Society of Clinical Oncology 
(ASCO) meeting, more than half of participants with 
recurrent metastatic NSCLC had a RECIST (Response 
Evaluation Criteria In Solid Tumors) response and 82% 
had clinical beneﬁ   t [4]. As reported, the tolerability 
proﬁ  le was excellent, with single digit grade 2 toxicities. 
Th  e compound now will be presented to regulatory 
authorities for approval in a subpopulation of 3 to 5% of 
patients with NSCLC with an expected duration of  © 2010 BioMed Central Ltd
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addition, the discovery strategy in most Pharmas has 
evolved from designing a chemical entity and testing it in 
patients to ﬁ   rst identifying key drivers of disease and 
then develop  ing agents aimed at these disease pathways.
Th   e era of broad based drug development is over and 
translational research is essential for additional progress 
against cancer. Th  is creates new opportunities and 
challenges. Some of the opportunities include better 
insights into the complex cancer biology, which allows 
identiﬁ  cation of subsets that respond better to treatment. 
A focused drug development approach will lead to a win-
win for patients, payers, and sponsors. Pharma now 
focuses on subset speciﬁ   c trials rather than trials in 
broadly deﬁ   ned tumors; interactions between basic 
scientists, clinical researchers and diagnostic partners are 
essential to achieve meaningful progress against cancer.
Th  e challenges are many: how to recognize the right 
data to identify patient subsets and the technology to 
select patients with suﬃ   cient rigor to drive drug develop-
ment in addition to meeting regulatory requirements that 
may not keep pace with advancing technology. Pharma 
must learn how to select the best academic and diag-
nostic partners. Research is essential for progress against 
cancer, but funding is limited for collaboration between 
academia and industry. It takes considerable eﬀ  ort and 
time to bring partners really together, some of which is 
simply related to trust.
For the timely development of a diagnostic, a commer-
cial partner may be preferred over an academic partner; 
however, the expertise of academic partners cannot be 
lost. Academic institutions compete with each other and 
thus choice of collaborators can be challenging.
In 2010 the Pharma priorities in oncology are driven by 
an unmet need and a targeted scientiﬁ  c hypothesis. By 
targeting the right pathway with optimal academic and 
diagnostic partners, medicines can be delivered to the 
right patient at the right time sooner.
Pharma today is and must be more cost-aware, must 
deﬁ  ne eﬃ   cacy for targeted agents consistently and, most 
of all, must let science drive the market rather than the 
reverse.
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